Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
September 15, 2024 08:45 ET
|
Lantheus Holdings, Inc.
Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3%...
Lantheus Appoints Julie Eastland as New Board Member
September 05, 2024 08:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find,...
Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024 08:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
August 20, 2024 08:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus Reports Second Quarter 2024 Financial Results
July 31, 2024 07:00 ET
|
Lantheus Holdings, Inc.
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023Completed three strategic transactions to expand innovative pipelineGAAP fully diluted...
Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
July 17, 2024 08:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on...
Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease
July 15, 2024 08:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus Welcomes CMS’ Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
July 10, 2024 12:32 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus Appoints Jamie Spaeth as Chief People Officer
July 08, 2024 08:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
June 27, 2024 07:05 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...